Recida Therapeutics Announces the Initiation of a Phase I Clinical Trial of RC-01, a Novel LpxC Inhibitor

April 1, 2019 Off By BusinessWire

RC-01 represents a new class of antibiotics in development for the
treatment of serious antibiotic-resistant infections

MENLO PARK, Calif.–(BUSINESS WIRE)–Recida Therapeutics, Inc. announced today the initiation of a Phase I
trial for RC-01, a novel LpxC inhibitor. The trial is being conducted in
the United States and is evaluating the safety, tolerability and
pharmacokinetics of RC-01 in healthy subjects after single or
multiple-dose intravenous administration. CARB-X has provided the
funding to support this Phase I trial.

RC-01 displays highly potent inhibitory activity against the bacterial
enzyme LpxC, with an IC50 at subnanomolar levels. RC-01 has potent
activity against gram-negative bacteria, including multidrug-resistant Enterobacteriaceae,
Pseudomonas aeruginosa and Acinetobacter baumannii which
represent an urgent unmet medical need. RC-01 has a favorable
drug-metabolism-pharmacokinetic profile and was well tolerated in
preclinical toxicology studies. None of the toxicities encountered with
previous LpxC inhibitors was observed with RC-01. Both in vitro
and animal in vivo efficacy and safety data support its clinical
development as a potential human therapeutic agent for the treatment of
serious bacterial infections caused by gram-negative pathogens in the
hospital setting.

“Despite the emergence of significant antibiotic resistance, no truly
new class of anti-gram-negative antibiotic has been successfully
developed in the last 65 years,” said James Ge, MD, PhD, President and
CEO of Recida. “With its novel mode of action, RC-01, if successfully
developed, may provide an attractive option for physicians to treat
serious and life-threatening conditions caused by multidrug-resistant
pathogens. We are very excited about the potential to demonstrate the
broad potential of this new antibiotic candidate in the clinic.”

About Recida Therapeutics

Recida Therapeutics is a clinical-stage biotechnology company focused on
developing first-in-class anti-infective medicines for the treatment of
multidrug-resistant infections. The company is currently advancing its
novel LpxC inhibitor, RC-01, in a Phase I clinical trial. Recida is led
by an experienced team of pharmaceutical and anti-infectives executives
seeking to improve outcomes for patients with multidrug-resistant and
other difficult-to-treat infections. Recida is located in Menlo Park,
CA. www.recidatherapeutics.com